Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors inside the central anxious process, conolidine modulates alternate molecular targets. A Science Advancements research discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availa... https://carolel481awr1.qodsblog.com/profile